Lysosomal Cathepsins B and L and Stef in A Blood Levels in Patients with Hepatocellular Carcinoma and/or Liver Cirrhosis: Potential Clinical Implications

Oncology (Switzerland)

Volumn 54, Issue 1, 1997, Pages 79-83

  Leto, Gaetano ^a   Tumminello, Francesca Maria ^a   Pizzolanti, Giuseppe ^a   Montalto, Giuseppe ^b   Soresi, Maurizio ^b   Gebbia, Nicola ^a  

^a Section of Chemotherapy   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

Cathepsin B; Cathepsin L; Hepatocellular carcinoma; Liver cirrhosis; Lysosomal proteinases; Proteinase inhibitors; Stefin A; Tumor progression

Indexed keywords

ALPHA FETOPROTEIN; CATHEPSIN B; CATHEPSIN L; LYSOSOME ENZYME; PROTEINASE INHIBITOR; STEFIN A;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE SEVERITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CATHEPSIN B; CATHEPSINS; CYSTATINS; CYSTEINE ENDOPEPTIDASES; ENDOPEPTIDASES; ENZYME PRECURSORS; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LYSOSOMES; MALE; MIDDLE AGED;

EID: 0031060195     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227666     Document Type: Article

References (24)

1. Solovyeva NI, Balayevskaya TO, Dilakyan EA, Zakamaldina-Zama TA, Pozdncv VF, Topol LZ, Kisseljov FL: Proteolytic enzymes at various stages of oncogenic transformation of rat fibroblasts, I, Aspartyl and cysteine protein-ases, Int J Cancer 1995;60:495-500.
2. Sloanc BF, Moin K, Krepela E, Rozhin J: Cathepsin B and its endogenous inhibitors: The role in tumor malignancy, Cancer Metastasis Rev 1990;9/4:333-352.
3. Kane SE, Gottesman MM: The role of cathepsin Lin malignant transformation, Semin Cancer Biol 1990;1:127-136.
4. Rozhin J, Honn KV, Sloane BF: Release of native cathepsin L from murine tumor cells, Proc Am Assoc Cancer Res 1991;32:71.
5. Ohsawa T, Higashi T, Tsuji T: The secretion of high molecular weight cathepsin B from cultured human liver cancers, Acta Med Okayama 1989;43/1:9-15.
6. Moin K, Day NA, Sameni M, Hasnain S, Hira-ma T, Sloane BF: Human tumor cathepsin B, Comparison with normal liver cathepsin B, Biochem J 1992;285:427-434.
7. Mach L, Schwihla H, Stiiwe K, Rowan A, Mort JS, Glossl J: Activation of procathepsin B in human hepatoma cells: The conversion into the mature enzymes relies on the action of cathepsin B itself, Biochem J 1993;293:437-442.
8. Buck M, Karustis DG, Day NA, Honn KV, Sloanc BF: Degradation of cxtraccllular-matrix proteins by human cathepsin B from normal and tumor tissues, Biochem J 1992;282:273-278.
9. Kirschkc H, Kcmbhavi AA, Bohley P, Barrett AJ: Action of rat liver cathcpsin L on collagen and other substrates, Biochem J 1982,201: 367-371.
10. Blondeau X, Lambert-Vidmar S, Emod I, Pa-gano M, Turk V, Keil-Dlouha V: Generation of matrix-degrading proteolytic system from fi-bronectin by cathepsins B, G, H and L, Biol Chem Hoppe Seyler 1993;374:651-656.
11. Monsky WL, Chen W-T: Proteases of cell adhesion protein in cancer, Semin Cancer Biol 1993;4:251-258.
12. Johnson PJ, Williams R: Cirrhosis and aetyolo-gy of hepatocellular carcinoma, J Hepatol 1987;4:140-147.
13. Colombo M, De Franchis R, Del Ninno E, San-giovanni E, De Fazio C, Tommasini M, Donato F, Piva A, Di Carlo V, Dioguardi N: Hepatocellular carcinoma in Italian patients with cirrhosis, N Engl J Med 1991;325:675-680.
14. Turk V, Bode W: The cystatins: Protein inhibitors of cysteine proteinases, FEBS Lett 1991; 285:213-219.
15. deClerk YA, Imren S: Protease inhibitors: Role and potential therapeutic use in human cancer, Eur J Cancer 1994;30A:2170-2180.
16. Lah TT, Clifford JL, Helmer KM, Day NA, Moin K, Honn KV, Crissmann JD, Sloane BF: Inhibitory properties of low' molecular mass cystcinc proteinase inhibitors from human sarcoma, Biochim Biophys Acta 1989;993:63-73.
17. Chambers A, Colella R, Denhardt DT, Wilson S: Increased expression of cathepsin L and B and decreased activity of their inhibitors in metastatic, ra.y-transformcd NIH 3T3 cells, MolCarcinog 1992;5:238-245.
18. Pugh RNH, Murray Lyon IM, Dawson JL, Pie-troni MC, Williams R: Transection of the oesophagus for bleeding oesophageal varices, Br J Surg 1973;60:646-649.
19. Okuda K: Early recognition of hepatocellular carcinoma, Hepatology 1986;6:729-738.
20. Taketa K: Alpha-fetoprotein: Réévaluation in hepatology, Hepatology 1990;12:1420-1432.
21. Tatsuta M, Yamamura H, Iishi H, Kasugai H, Okuda S: Value of serum alpha-fetoprotein and ferritin in the diagnosis of hepatocellular carcinoma, Oncology 1986;43:306-310.
22. Murawaki Y, Yamada S, Koda M, Hirayama C: Collagenasc and collagenolytic cathepsin in normal and fibrotic rat liver, J Biochem 1990; 108:241-244.
23. Scott KG: Proteinases and proteinase inhibitors as modulator of animal cell growth, Comp Biochem Physiol 1992; 103/4B:785-793.
24. Brouillet JP, Hanslick B, Maudelonde T, Pivat MP, Grenier J, Blanc F, Rochefort H: Increased plasma cathepsin D concentrations in hepatic carcinoma and cirrhosis but not in breast cancer, Clin Biochem 1991,24:491-496.